Alogliptin, but not voglibose, ameliorates dyslipidemia and LDL particle size in patients with impaired glucose tolerance or Type 2 diabetes

References

• Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with Type 2 diabetes. Diabetes Obes. Metab. 6(2), 133–156 (2004).
   Google Scholar
• Twickler TB, Dallinga-Thie GM, Cohn JS, Chapman MJ. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 109(16), 1918–1925 (2004).
   Google Scholar
• Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J. Lipid Res. 23(1), 97–104 (1982).
   Google Scholar
• Krayenbuehl PA, Wiesli P, Schmid C, Lehmann R, Spinas GA, Berneis K. Insulin sensitivity in Type 2 diabetes is closely associated with LDL particle size. Swiss Med. Wkly 138(19–20), 275–280 (2008).
   Google Scholar
• Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with Type 2 diabetes. Diabetes Obes. Metab. 13(4), 366–373 (2011).
   Google Scholar
• Nakano T, Inoue I, Seo M et al. Rapid and simple profiling of lipoproteins by polyacrylamide-gel disc electrophoresis to determine the heterogeneity of low-density lipoproteins (LDLs) including small, dense LDL. Recent Pat. Cardiovasc. Drug Discov. 4(1), 31–36 (2009).
   Google Scholar
• Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to metformin in Japanese patients with Type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes. Metab. 14(10), 927–936 (2012).
   Google Scholar
• Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with Type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr. Med. Res. Opin. 27(Suppl. 3), S21–S29 (2011).
   Google Scholar
• Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin in Japanese patients with Type 2 diabetes mellitus: a randomized, double-blind, doseranging comparison with placebo, followed by a long-term extension study. Curr. Med. Res. Opin. 27(9), 1781–1792 (2011).
   Google Scholar
• Kaku K, Itayasu T, Hiroi S, Hirayama M, Seino Y. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with Type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes. Metab. 13(11), 1028–1035 (2011).
   Google Scholar
• Seino Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with Type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. J. Diabet. Invest. 3(6), 517–525 (2012).
   Google Scholar
• Eliasson B, Möller-Goede D, Eeg-Olofsson K et al. Lowering of postprandial lipids in individuals with Type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 55(4), 915–925 (2012). ▪▪ Recent well‑controlled trial demonstrating that alogliptin (monotherapy or in combination with pioglitazone) produced significant reductions in postprandial triglyceride and triglyceride‑rich lipoproteins in patients with Type 2 diabetes mellitus following a high‑fat meal.
   Google Scholar
• Matikainen N, Mänttäri S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with Type 2 diabetes. Diabetologia 49(9), 2049–2057 (2006).
   Google Scholar
• Matsumoto K, Yano M, Miyake S et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in noninsulin-treated NIDDM patients. Diabetes Care 21(2), 256–260 (1998).
   Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr. Rev. 33(2), 187–215 (2012). ▪ Recent report showing that amelioration of dyslipidemia in patients with insulin‑resistant syndromes and Type 2 diabetes mellitus is possibly a class effect for gliptins that may be secondary to the potentiation of endogenous incretin activity through DPP‑4 inhibition.
   Google Scholar
• Shirakawa J, Fujii H, Ohnuma K et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60(4), 1246–1257 (2011).
   Google Scholar